Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 18/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.38 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14718856 | 0.78 | PARP1 (0.40) | PARP1PARP2PARP3TNKSTNKS2 | |
| SCHEMBL29919865 | 0.78 | PARP1 (0.41) | PARP1PARP2PARP3TNKSTNKS2 | |
| SCHEMBL21372079 | 0.78 | PARP1 (0.41) | PARP1PARP2PARP3TNKSTNKS2 | |
| SCHEMBL14718248 | 0.75 | PARP1 (0.39) | PARP1PARP2PARP3TNKSTNKS2 | |
| SCHEMBL14719247 | 0.67 | PARP1 (0.48) | PARP1PARP2TNKSTNKS2ATM | |
| SCHEMBL14718623 | 0.67 | PARP1 (0.39) | PARP1PARP2PARP3TNKSTNKS2 | |
| SCHEMBL29915234 | 0.66 | PARP1 (0.55) | PARP1PARP2PARP3 | |
| SCHEMBL24317868 | 0.63 | ATM (0.47) | PARP1PARP2PARP3TNKSTNKS2 | |
| SCHEMBL30530525 | 0.63 | ATM (0.47) | PARP1PARP2PARP3TNKSTNKS2 | |
| SCHEMBL6842345 | 0.63 | NPC1 (0.44) | PARP1PARP2PARP3TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053365-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARMACEUTICAL, INC. (US) | 2013-02-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053365-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885PARP3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.